A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer - Top-Institutions - MDSpire

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • By

  • Dan Zhou

  • Beibei Ran

  • Lingkai Kong

  • Yan Liu

  • Lingjun Xiao

  • Xiangmei Chen

  • Wencui Liu

  • Xiao Li

  • Jing Zhang

  • Jiahui Zhang

  • Hao Wu

  • Guang Zhang

  • Xiaosong Gu

  • Wenjie Zhang

  • Junhua Wu

  • Chunping Jiang

  • June 15, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    The University of Texas MD Anderson Cancer Center
    The University of Texas MD Anderson Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Immuno-oncology

  • #2

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, New York

    Key Differentiators

    • Oncology
    • Cancer Immunotherapy

  • #3

    Dan L. Duncan Comprehensive Cancer Center
    Dan L. Duncan Comprehensive Cancer Center

    Houston, Texas

    Key Differentiators

    • Oncology
    • Clinical Trials

Original Source(s)

A CDK4/6 inhibitor-armed oncolytic adenovirus reverses T cell exhaustion through the Rb-p65-CCL5 pathway and potentiates the antitumor activity of anti-PD-1 or CAR-T therapy in colorectal cancer

  • by Dan Zhou, Beibei Ran, Lingkai Kong, Yan Liu, Lingjun Xiao, Xiangmei Chen, Wencui Liu, Xiao Li, Jing Zhang, Jiahui Zhang, Hao Wu, Guang Zhang, Xiaosong Gu, Wenjie Zhang, Junhua Wu, Chunping Jiang

  • June 15, 2026

Related Content

HDAC1-mediated CDK1 decrotonylation inhibits colorectal cancer proliferation by regulating cell cycle and apoptosis

Mailed Outreach for Colorectal Cancer Screening in Community Health Centers: The CARES Pragmatic Cluster

Editorial: AntibodyPlus therapeutics in oncology: innovative mechanisms, therapeutic strategies, and clinical advances